Real-world multicenter study of rezvilutamide plus androgen deprivation therapy in Chinese patients with high-volume metastatic hormone-sensitive prostate cancer

BackgroundRezvilutamide combined with androgen deprivation therapy (ADT) has become a first-line standard regimen for high-volume metastatic hormone-sensitive prostate cancer (mHSPC), but real-world evidence from China remains limited.MethodsThis was a multicenter, retrospective real-world cohort st...

Description complète

Détails bibliographiques

Auteurs principaux:	Shuang Peng, Ruochen Zhang, Zijun Zou, Qichen Wei, Caixia Dai, Jinfeng Wu, Liefu Ye, Yongbao Wei, Li Huang
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2025-10-01
Collection:	Frontiers in Oncology
Sujets:	rezvilutamide androgen deprivation therapy high-volume metastatic hormone-sensitive prostate cancer real-world study PSA response
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1657772/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!